Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage
biopharmaceutical company on a mission to develop treatments that
restore cognitive function, today announced that it will present
clinical trial design for a Phase 2a study of its lead development
candidate, CY6463, in participants with Alzheimer’s disease with
vascular pathology at the upcoming Alzheimer’s Association
International Conference 2021 (AAIC). AAIC will be held July 26-30,
2021, virtually and in Denver, CO.
In addition, Anna Marin, a researcher in the laboratory of Dr.
Andrew Budson and Dr. Katherine Turk in the Department of
Neurology, Boston University School of Medicine and Center for
Translational and Cognitive Neuroscience, VA Boston Healthcare
System, will present results from the Cyclerion sponsored study on
peak alpha frequency and N200 latency as predictors of
neuropsychological performance in a memory disorders clinic. This
pioneering work provides insights into the relationships between
electrophysiological measures and cognitive performance in patients
with Alzheimer’s disease and other dementias. Cyclerion identified
changes in electrophysiological measures in the recent Phase 1
Translational Pharmacology study and will be evaluating
electrophysiological and cognitive endpoints in the Phase 2a study
in participants with Alzheimer’s disease with vascular
pathology.
Cyclerion Poster Presentation Details:
Title: Clinical trial design for a Phase 2a
study evaluating the safety, tolerability, pharmacokinetics, and
CNS activity of CY6463 in participants with Alzheimer’s disease
with vascular pathology
Poster Number: P-54463
Presenter: Chad Glasser, Ph.D., Director of
Clinical Research, Cyclerion Therapeutics
Authors: Chad Glasser, Jennifer Chickering,
Phebe Wilson, Emily Florine, Chris Winrow, Chris Wright
The poster presentation will be available beginning at 8 a.m. MT
/ 10 a.m. ET Monday, July 26, on the AAIC meeting platform. The
poster will also be available on the News & Events page of the
Cyclerion website
https://ir.cyclerion.com/news-events/event-calendar.
Center for Translational and Cognitive Neuroscience
Poster Presentation Details:
Title: Peak alpha frequency and N200 latency as
predictors of neuropsychological performance in a memory disorders
clinic
Poster Number: P-54365
Presenter: Anna Marin B.A., Department of
Neurology, Boston University School of Medicine; Center for
Translational and Cognitive Neuroscience, VA Boston Healthcare
System
Authors: Anna Marin B.A.1,2, Kylie Schiloski
B.A.2, Naheer Lahdo B.A.2, Ana Vives Rodriguez M.D.2, Renee DeCaro
Ph.D.2, Andrew E. Budson M.D.1,2, Katherine W. Turk M.D.1,2
1 Department of Neurology, Boston University School of
Medicine; 2Center for Translational and Cognitive Neuroscience, VA
Boston Healthcare System
The poster presentations will be available beginning at 8 a.m.
MT / 10 a.m. ET Monday, July 26, on the AAIC meeting platform. The
posters will also be available on the News & Events page of the
Cyclerion website
https://ir.cyclerion.com/news-events/event-calendar.
About Cyclerion TherapeuticsCyclerion
Therapeutics is a clinical-stage biopharmaceutical company on a
mission to develop treatments that restore cognitive function.
Cyclerion is advancing novel, first-in-class, CNS-penetrant, sGC
stimulators that modulate a key node in a fundamental CNS signaling
pathway. The multidimensional pharmacology elicited by the
stimulation of sGC has the potential to impact a broad range of CNS
diseases. The most advanced compound, CY6463, has shown rapid
improvement in biomarkers associated with cognitive function and is
currently in clinical development for Alzheimer's Disease with
Vascular pathology (ADv), Mitochondrial Encephalomyopathy, Lactic
Acidosis and Stroke-like episodes (MELAS), and Cognitive Impairment
Associated with Schizophrenia (CIAS). Cyclerion is also advancing
CY3018, a next-generation sGC stimulator.
For more information about Cyclerion, please
visit https://www.cyclerion.com/ and follow us on Twitter
(@Cyclerion) and LinkedIn (www.linkedin.com/company/cyclerion).
Forward Looking StatementThis press release
contains forward-looking statements within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended. Our
forward-looking statements are based on current beliefs and
expectations of our management team that involve risks, potential
changes in circumstances, assumptions, and uncertainties. We may,
in some cases use terms such as “predicts,” “believes,”
“potential,” “continue,” “anticipates,” “estimates,” “expects,”
“plans,” “intends,” “may,” “could,” “might,” “likely,” “will,”
“should” or other words that convey uncertainty of the future
events or outcomes to identify these forward-looking statements.
Each forward-looking statement is subject to risks and
uncertainties that could cause actual results to differ materially
from those expressed or implied in such statement. Applicable risks
and uncertainties include the risks listed under the heading “Risk
Factors” and elsewhere in our 2020 Form 10-K filed on February 25,
2021, and our subsequent SEC filings including the Form 10-Q filed
on April 30, 2021. Investors are cautioned not to place undue
reliance on these forward-looking statements. These forward-looking
statements (except as otherwise noted) speak only as of the date of
this press release, and Cyclerion undertakes no obligation to
update these forward-looking statements, except as required by
law.
InvestorsCarlo Tanzi, Ph.D.Kendall Investor
Relationsctanzi@kendallir.com
MediaAmanda SellersVerge Scientific
Communicationsasellers@vergescientific.com
Cyclerion Therapeutics (NASDAQ:CYCN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cyclerion Therapeutics (NASDAQ:CYCN)
Historical Stock Chart
From Sep 2023 to Sep 2024